ORIGINAL RESEARCH article
Front. Microbiol.
Sec. Microorganisms in Vertebrate Digestive Systems
Volume 16 - 2025 | doi: 10.3389/fmicb.2025.1672313
Yixintai treats chronic heart failure in rats by regulating gut microbiota and bile acid
Provisionally accepted
- Hunan University of Chinese Medicine, Changsha, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Yixintai (YXT), a traditional Chinese medicine for chronic heart failure (CHF), has demonstrated safety and efficacy in the treatment of CHF. However, its precise mechanistic actions require further elucidation. This study identified components in YXT using the UHPLC-QE-MS technique. A rat CHF model was created by ligating the left anterior descending coronary artery and an inflammatory injury model was induced in H9c2 cells using lipopolysaccharide (LPS) to evaluate the efficacy of YXT. After YXT treatment, changes in fecal gut microbiota and serum BAs profiles in rats were evaluated utilizing 16S rRNA sequencing and UHPLC-MS/MS techniques. Additionally, western blot (WB) and polymerase chain reaction (PCR) assays were conducted to assess the expression levels of TGR5 in both myocardial tissue and H9c2 cells. Cyclic adenosine monophosphate (cAMP), B-type natriuretic peptide (BNP), interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) levels were also measured using enzyme-linked immunosorbent assay (ELISA). In total, 1049 components were identified in YXT. YXT treatment effectively attenuated the inflammatory reaction, reduced serum BNP levels, alleviated the pathological changes in the colon and myocardium, and improved cardiac function in CHF rats. YXT treatment significantly improved gut microbiota diversity in CHF rats, enhancing beneficial bacterial populations and serum bile acid levels, while reducing the abundance of detrimental bacteria. Furthermore, YXT treatment enhanced TGR5 expression in the myocardial tissue and H9c2 cells of CHF rats.These findings suggest that YXT exerts its therapeutic benefits by reshaping the gut microbiota, modulating bile acid metabolism, and activating TGR5.
Keywords: chronic heart failure, Yixintai, Gut Microbiota, Bile acid, tgr5
Received: 01 Aug 2025; Accepted: 06 Oct 2025.
Copyright: © 2025 Shi, Yuan, Liu, Wang, Huang, Zeng, Wei, Li and Guo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Min Shi, shimin@stu.hnucm.edu.cn
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.